Form 4: Orgenesis Inc. Director Adam Pelavin Acquires Stock Options

Director Adam Pelavin of Orgenesis Inc. was granted stock options under the company's 2017 Equity Incentive Plan.

Summary

• Adam Pelavin, a director at Orgenesis Inc., was granted stock options on December 12, 2024.
• The options were awarded under the company's 2017 Equity Incentive Plan.
• A total of 1,875 stock options were granted, with an exercise price of $0.98 per share.
• 625 of the options vest in three years, one third each year starting December 12, 2025, December 12, 2026, and December 12, 2027.
• The remaining 1,250 options vest in one year, beginning on December 12, 2024.
• The vesting of all options is contingent on Pelavin's continued service on the Board of Directors.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the options is dependent on the future performance of Orgenesis Inc.'s stock price.
• If the director leaves the board before the vesting dates, the options may be forfeited.

Future Outlook

The director's stock options will vest over the next three years, contingent on continued service on the board.

Industry Context

Granting stock options to directors is a common practice to align their interests with those of the shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one to three years is also typical for such grants, aligning with long-term strategic goals.
• The exercise price of $0.98 is likely based on the current market price of the stock at the time of the grant.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Next Steps

• The director will need to remain on the board to fully vest the options.
• The director may exercise the options at any time after they vest and before the expiration date.

Key Dates

Keywords

stock options, Orgenesis Inc., director, Adam Pelavin, equity incentive plan, vesting